Drug Trial Radar · NCT05180526
Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Dec 27, 2021
Primary completion
Aug 5, 2025
Study completion Aug 5, 2025
Sponsor
- Lead sponsor
- Bio-Thera SolutionsIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled. Screening period (-2\~0 weeks) ,Treatment period (1-22 weeks), Follow-up period, At the same time, plasma concentration will be determined
Conditions
- Uveitis
Interventions
QLETLIDrug
80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of treatment failureTime frame: 6\12\24week
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China
The Second Xiangya Hospital of Central South University
Changsha, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
The second hospital of Jilin University
Jilin City, China
Tianjin Medical University Eye Hospital
Tianjin, China
Renmin Hospital of Wuhan University
Wuhan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.